Pillsbury today welcomed new corporate partner Steven M. Tyndall. With a broad client base ranging from formation stage and emerging companies to established public and private companies, Tyndall focuses on advising clients in the areas of technology, life sciences and clean energy.
“We are very pleased to welcome Steve to Pillsbury,” said Firm Chair Jim Rishwain Jr. “His deep industry knowledge and experience will be of great benefit to our clients in Texas and around the world. With our global platform and the recent addition of Andrew Strong, former CEO of Kalon Biotherapeutics, we are poised to further build on our recognized position as a worldwide leader in the life sciences industry.”
Tyndall represents issuers, underwriters, and venture capital and private equity in public and private offerings of equity and debt securities. He also advises clients in mergers and acquisitions; and public and private companies with corporate and transactional matters, including the preparation of periodic reports under the Securities Exchange Act of 1934 for publicly held companies.
Tyndall has represented issuers and investors in venture capital and private equity financings with an aggregate value of over $600 million; publicly traded and privately held buyers and sellers in merger and acquisition transactions valued at well over $1 billion; and issuers and underwriters in public offerings of equity and debt transactions with an aggregate value of more than $3 billion. Prior to joining Pillsbury, he was a partner at Baker Botts LLP.
“Steve’s history and experience serving a broad range of industries, with a particular focus on technology companies operating in areas such as life sciences, traditional and alternative energy technologies, software, and gaming will be an important complement to the services we offer,” said Corporate & Securities—Technology practice section leader Stanley F. Pierson. “We are focused on growing in Texas, particularly in the technology sector, and bringing Steve on board is part of that effort.”
After more than 10 years in Texas, Pillsbury opened its second office in the state in 2014 with four attorneys. The office has since grown to 15 attorneys, with the addition of Tyndall and a group of ten intellectual property attorneys in January.
“I’m very much impressed with Pillsbury’s strong, team-oriented approach and the companies and investment funds that consider Pillsbury their go-to firm,” Tyndall said. “Pillsbury’s strength in the areas that impact my corporate practice and the firm’s global reach will be of great interest to my Texas clients, particularly those in emerging tech and life sciences. In addition, I look forward to working with Andrew Strong, who has deep connections in the biotech industry here in the Gulf region, to further Pillsbury’s already strong life sciences practice.”
Andrew Strong rejoined Pillsbury as a partner in March after stints as President, CEO and General Counsel of Kalon Biotherapeutics, and as General Counsel and System Compliance Officer to Texas A&M System’s Board of Regents.
Tyndall earned a Bachelor of Arts from Southern Methodist University and his law degree from the University of Tulsa College of Law. He is admitted to practice in the state of Texas.
Source: www.pillsburylaw.com
